Ate-Bev Early Response Prediction Model in Advanced HCC

This study aims to develop a model that can predict early on — using imaging scans — whether a patient with advanced liver cancer (hepatocellular carcinoma, or HCC) is responding to a standard drug combination called atezolizumab plus bevacizumab. An early response prediction tool could help doctors make faster treatment decisions. **You may be eligible if...** - You have been diagnosed with advanced liver cancer (hepatocellular carcinoma) - You are scheduled to receive atezolizumab plus bevacizumab as your first treatment - You are willing to participate and have consented **You may NOT be eligible if...** - You have a history of severe allergy to contrast dye used in imaging - You have severe organ problems that meet certain exclusion criteria per clinical guidelines Talk to your doctor to see if this trial is right for you.